News | Neuro Imaging | July 31, 2017

Waterlogged Brain Region Helps Scientists Gauge Damage Caused by Parkinson’s Disease

NIH-funded research could aid drug development for the condition

NIH-funded scientists have discovered that Parkinson’s disease increases the amount of “free” water in a particular brain area

NIH-funded scientists have discovered that Parkinson’s disease increases the amount of “free” water in a particular brain area. Image courtesy of David Vaillancourt, Ph.D., University of Florida.

Scientists at the University of Florida have discovered a new method of observing the brain changes caused by Parkinson’s disease, which destroys neurons important for movement. The development suggests that fluid changes in a specific brain area could provide a way to track that damage. The study, published in the journal Brain, was supported by the NIH’s National Institute of Neurological Disorders and Stroke (NINDS).

“By finding a new way to detect and track how Parkinson’s affects the brain, this study provides an important tool for assessing whether a drug might slow or stop those changes and keep symptoms from getting worse,” said NINDS Program Director Daofen Chen, Ph.D.

The researchers, led by David Vaillancourt, Ph.D., a professor of applied physiology and kinesiology at the University of Florida in Gainesville, FL, used a form of MRI that differentiates between water contained in brain cells and “free” water outside of cells. Their analysis focused on the substantia nigra, a brain structure where Parkinson’s disease kills neurons that use the chemical dopamine to communicate with other cells. The results showed that the amount of free water in that brain area stayed the same over the course of a year in healthy individuals but increased in early-stage Parkinson’s patients during that period and increased further over the next three years. This confirms and expands on a prior study by the same group that measured free water over just one year. The new findings also revealed the increase in free water was linked to worsening symptoms.

“The amount of free water doesn’t just change over one year – it keeps progressively increasing, which suggests that it’s tracking the progressive degeneration of neurons,” said Vaillancourt.

The researchers used a scale to evaluate patient’s movement problems, with Stage One on the scale being the least severe and Stage Five being the most advanced. Patients who moved up a stage on the scale during the four years of the study had a greater free water increase than patients who remained at the same stage, suggesting the change reflected Parkinson’s-related damage to neurons.     

Parkinson’s disease destroys dopamine-producing cells in the substantia nigra, which connect to adjacent brain areas. Dr. Vaillancourt’s study showed that a greater free water increase in the substantia nigra was associated with a decrease in dopamine neuron activity in one of these nearby regions, supporting the idea that free water changes are related to progression of the disease.  

“That correlation is encouraging because it pins down the biological relevance of free water,” Vaillancourt said.

The study’s results suggest that the MRI-based free water measurement could be used in Parkinson’s disease clinical trials. If a treatment slows or stops the increase in free water, it might be evidence that the drug is slowing the progressive loss of dopamine neurons. 

The researchers used data from the Parkinson’s Progression Markers Initiative (PPMI), a large study sponsored by the Michael J. Fox Foundation that has been collecting information on recently diagnosed Parkinson’s patients from over 30 different U.S. and international sites. The fact that Vaillancourt’s team found similar patterns in patients at every location boosted his confidence in the results because, like the PPMI, clinical trials must collect data from many sites using numerous different MRI machines.

“The PPMI data is real-world messy data, and when you find the effect in real-world messy data, it makes you think that it has legs,” he said.

Dr. Vaillancourt speculated that his team’s free water approach could make clinical trials less expensive by reducing the number of participants they would need to enroll. His team is currently running just such a study using free water to gauge the effect of a potential Parkinson’s treatment. At the same time, the group is attempting to develop computer programs that will make free water analysis faster and easier. Future studies are needed to track changes in free water over longer time spans and in other brain regions and to determine what causes them. 

The study was funded by NINDS (NS052318), the National Institute of Mental Health (MH108574), the National Institute of Biomedical Imaging and Bioengineering (EB015902), and the Parkinson’s Progression Markers Initiative. 

For more information: www.nih.gov

Related Content

Toshiba Showcases MRI Workflow Enhancements at RSNA 2017
News | Magnetic Resonance Imaging (MRI) | September 21, 2017
September 21, 2017 — Toshiba Medical will highlight its latest...
Siemens Healthineers to Showcase Magentom Vida MRI at RSNA 2017
Technology | Magnetic Resonance Imaging (MRI) | September 18, 2017
September 18, 2017 — Siemens Healthineers announced it will display the new Magnetom Vida 3T...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
News | Contrast Media | September 12, 2017
The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly...
News | Imaging | September 11, 2017
September 11, 2017 — Innovatus Imaging Corp., a newly created holding company formed by private equity firm Resilienc
Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project
News | Ultrasound Womens Healthcare | September 08, 2017
September 8, 2017 — Delphinus Medical Technologies Inc.
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Overlay Init